How Does DATA-Waiver Provider Patient Capacity Relate to Opioid and Buprenorphine Prescribing? Issue Brief
Robin Ghertner and Mir M. Ali
U.S. Department of Health and Human Services
Office of the Assistant Secretary for Planning and Evaluation
Link to HTML Version (8 PDF pages)
This brief examines how increases in patient capacity among buprenorphine waivered providers relates to prescribing of buprenorphine and opioids at the county-level.
This brief was prepared through intramural research by the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation. For additional information about this subject, you can visit the BHDAP home page at https://aspe.hhs.gov or contact the authors at Robin.Ghertner@hhs.gov, Mir.Ali@hhs.gov.
DISCLAIMER: The opinions and views expressed in this brief are those of the authors. They do not reflect the views of the Department of Health and Human Services, the contractor or any other funding organization. This brief was completed and submitted on February 2020.